ChatGPTなどを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
<>
24/10/12
[PDF] The applications of CT with artificial intelligence in the prognostic model of idiopathic pulmonary fibrosis
Z Chen, Z Lin, Z Lin, Q Zhang, H Zhang, H Li, Q Chang… - Therapeutic Advances in …, 2024
… Idiopathic pulmonary fibrosis (IPF) is the most common fibrotic interstitial lung disease (ILD) with chronic, progressive, and heterogeneous … While some IPF patients get progressively worse over the progression of the disease, others remain …
- 特発性肺線維症の予後モデルにおける人工知能付き CT の応用
[HTML] Referral to pulmonary rehabilitation and palliative care services in people with idiopathic pulmonary fibrosis in England, 2010–2019
AD Morgan, H Khan, PM George, JK Quint - npj Primary Care Respiratory Medicine, 2024
… Idiopathic pulmonary fibrosis (IPF) is a relatively rare chronic condition characterised by scarring of the lung … IPF is rare in people under the age of 45 years, incidence increases with age 1,3 . For a variety of reasons, it has been difficult …
[HTML] Donor age over 55 is associated with worse outcome in lung transplant recipients with idiopathic pulmonary fibrosis
I Moneke, ED Ogutur, A Kornyeva, S Fähndrich… - BMC Pulmonary Medicine, 2024
… from idiopathic pulmonary fibrosis (IPF), there are many other causes of pulmonaryfibrosis such as autoimmune/connective tissue diseases, eg, rheumatoid arthritis, environmental exposures to coal or silica, or allergens, eg, bird fancier’s …
- 55歳を超えるドナーの年齢は、特発性肺線維症の肺移植患者の転帰不良と関連している
24/10/11
[HTML] SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway
B Yue, D Xiong, J Chen, X Yang, J Zhao, J Shao, D Wei… - Respiratory Research, 2024
… The prevalence of non-small cell lung cancer (NSCLC) is notably elevated in individuals diagnosed with idiopathic pulmonary fibrosis(IPF… at the intersection of IPF and NSCLC. Our study sought to elucidate the function of SPP1 within the …
- SPP1はPI3K/Akt/mTOR経路を介して特発性肺線維症およびNSCLCの進行を誘導する
[PDF] The soluble factor milieu in idiopathic pulmonary fibrosis dysregulates epithelial differentiation
RK Kortekaas, KE Geillinger‐Kästle… - The FASEB Journal, 2024
… In idiopathic pulmonary fibrosis (IPF), epithelial abnormalities are present including bronchiolization and alveolar cell … the IPFmicroenvironment disrupts normal epithelial growth and differentiation. We mimicked the soluble factors within …
- 特発性肺線維症における可溶性因子環境は上皮分化を調節不全にする
[HTML] Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis
Y Chen, S Cao, S Shao, Z Tong - BMC Pulmonary Medicine, 2024
… Idiopathic Pulmonary Fibrosis (IPF) is a fatal disease with scarce therapeutic alternatives, which imposes a significant economic burden on … Idiopathic Pulmonary Fibrosis (IPF) stands as a debilitating interstitial lung disease …
Luteolin‐Loaded Hyaluronidase Nanoparticles with Deep Tissue Penetration Capability for Idiopathic Pulmonary Fibrosis Treatment
B Pan, F Wu, S Lu, W Lu, J Cao, F Cheng, M Ou… - Small Methods, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease … both in vitro (using MRC5 cells) and in vivo (using IPF mice models), and its anti-fibrotic properties are … Idiopathic pulmonary fibrosis(IPF) is a chronic and …
- 特発性肺線維症治療のための深部組織浸透能を有するルテオリン含有ヒアルロニダーゼナノ粒子
[PDF] Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study)
A Romero Ortiz, M MORROS, A Ramon, A Villar… - 2024
… Background Idiopathic pulmonary fibrosis(IPF) is a fatal progressive lung disease entailing significant impairment in health-related quality … and costs among patients with idiopathicpulmonary fibrosis enrolled in the idiopathicpulmonary fibrosis …
- 特発性肺線維症の急性増悪の臨床的および経済的負担：スペインにおける前向き観察研究（OASIS 研究）
IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets Primary End Point.
HE Klein - Patient Care (Online), 2024
… primary endpoint in a phase 3 trial for the treatment of idiopathic pulmonary fibrosis(IPF). The trial included over 1,100 participants from more … This breakthrough represents a potential new treatment option for IPF, a condition with …
- ネランドミラストのFIBRONEER-IPF試験が主要評価項目を達成。
[PDF] The epithelial barrier theory and its associated diseases
N Sun, I Ogulur, Y Mitamura, D Yazici, Y Pat, X Bu, M Li… - Allergy, 2024
… Idiopathic pulmonary fibrosis Idiopathicpulmonary fibrosis (IPF) emerged during the second half of the 20th century, coinciding with an … Lung specimens from patients with idiopathic pulmonary fibrosis showed an altered expression of tight …
- 上皮バリア理論とそれに関連する疾患
8154 The Pro-Fibrotic Transcriptional Profile of Adipose Tissue in Insulin Resistant Individuals
M Choi, A Abdellatif, DL Alba, SK Koliwad - Journal of the Endocrine Society, 2024
… Upregulated genes included multiple genes encoding inflammatory chemokines (eg CCR2, CCR4), matrix metalloproteinases (eg MMP3, MMP7), and interestingly several genes associated with idiopathic pulmonary fibrosis(eg CSF3R, SERPINE1 …
- インスリン抵抗性患者の脂肪組織の線維化促進転写プロファイル
24/10/10
Physical activity and idiopathic pulmonary fibrosis: a prospective cohort study in UK Biobank and Mendelian randomization analyses
Q Liang, G Sun, J Deng, Q Qian, Y Wu - Respiratory Medicine and Research, 2024
Introduction The impact of physical activity on the incidence of idiopathic pulmonary fibrosis(IPF) remains less well studied. This study aimed to investigate the relationship between moderate-to-vigorous physical activity (MVPA) and the risk of …
[HTML] SULF1 expression is increased and promotes fibrosis through the TGF-β1/SMAD pathway in idiopathic pulmonary fibrosis
M Tu, C Lu, H Jia, S Chen, Y Wang, J Li, J Cheng… - Journal of Translational …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease of unknown etiology. Despite the increasing global … This study tried to explore the pathogenic mechanisms of IPF. We found elevated expression of SULF1 …
- 特発性肺線維症ではSULF1の発現が増加し、TGF-β1/SMAD経路を介して線維化を促進する。
[PDF] Development and Evaluation of ABI-171, a New Fluoro Catechin Derivative, for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
GL Araldi, YW Hwang, G Raghu - 2024
… idiopathic pulmonary fibrosis (IPF), a disease for which there are currently no curative treatments. Although our results are based on a bleomycin-induced pulmonary fibrosis model … antifibrotic drugs for IPF—were developed using similar …
- 特発性肺線維症（IPF）の治療のための新しいフルオロカテキン誘導体ABI-171の開発と評価
Telltale Signs of Lower Lobe Pulmonary Fibrosis
AG Thomas, JH Chung, L Landeras, L Chelala - Annals of the American Thoracic …, 2024
… of pulmonary fibrosis on chest CT and also portends the worst prognosis. Although strongly associated with a diagnosis of idiopathicpulmonary fibrosis (IPF), it is … Four categories have been described on CT to reflect the level of confidence …
- 下葉肺線維症の兆候
[HTML] Factors associated with non-intervention of antifibrotic agents in IPF patients
M Asami-Noyama, K Hamada, Y Asai, T Abe… - Respiratory Investigation, 2024
… The efficacy of antifibrotic agents in idiopathic pulmonary fibrosis (IPF) has been demonstrated and early introduction is recommended, especially in patients with preserved performance status (PS). We aimed to determine the proportion of …
- IPF患者における抗線維化薬の非介入に関連する要因
Delineating, Imaging, and Assessing Pulmonary Fibrosis Remodeling via Collagen Hybridization
J Zhao, W Yu, D Zhou, Y Liu, J Wei, L Bi, S Zhao, J He… - ACS nano, 2024
… (b) Representative images of H&E and Cy3-CHP-stained lung sections from patients with and without idiopathic pulmonary fibrosis (IPF). (c) The mouse model of bleomycin (BM) induced pulmonary fibrosis with representative micrographs of H&E …
- コラーゲンハイブリダイゼーションによる肺線維症リモデリングの描写、画像化、評価
[PDF] Advancing Pulmonary Fibrosis Awareness: Developing Microphysiological Systems for Effective Drug Discovery and Therapeutic Interventions
CG Sanchez
… We are at the end of Pulmonary FibrosisAwareness Month, an opportunity to acknowledge and celebrate the work of scientific colleagues in … Finally, there is idiopathicpulmonary fibrosis (IPF), in which no direct cause can be identified. The …
- 肺線維症の認知度向上：効果的な創薬と治療介入のための微小生理学的システムの開発
[PDF] Prognostic Impact of Pulmonary Diseases in 952 Patients with Thoracic and/or Abdominal Aortic Aneurysm
Y Kobayashi, T Ishiguro, N Kagiyama, M Sumi… - 2024
… We investigated the prevalence of pulmonary diseases at AA diagnosis, including IPF; non-IPFILD, such as collagen vascular disease-associated ILD, non-IPF idiopathic interstitial pneumonias, fibrosing hypersensitivity pneumonitis, and …
- 胸部および/または腹部大動脈瘤患者 952 名における肺疾患の予後への影響
Identification of FGFR4 as a regulator of myofibroblast differentiation in Pulmonary Fibrosis
M Ghanem, A Justet, M Jaillet, E Vasarmidi… - American Journal of …, 2024
… 39 Introduction 40 Idiopathic pulmonaryfibrosis (IPF) is a devastating lung disease with limited therapeutic 41 options. FGFR4 is a known receptor for several paracrine Fibroblast growth factors (FGFs). 42 FGFR4 is also the main receptor for …
- 肺線維症における筋線維芽細胞分化の制御因子としての FGFR4 の同定
24/10/09
[PDF] ImmunoTools FlowISiAM Award 2024
R Osuna, D Castillo
… 5 years after being diagnosed with idiopathicpulmonary fibrosis (IPF) (2). While IPF is the prototypical progressive fibrosing ILD (F-ILD), a high proportion of patients with other ILD subtypes develop a F-ILD phenotype (3). Often, pulmonary fibrosis …
- イミュノツールズ FlowISiAM アワード 2024
<>
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
